Kidney International Reports,
Год журнала:
2020,
Номер
5(9), С. 1545 - 1550
Опубликована: Июль 6, 2020
IntroductionThe
coronavirus
disease
2019
(COVID-19)
pandemic
has
affected
the
care
of
patients
with
noncommunicable
diseases,
including
those
suffering
from
kidney-related
ailments.
Many
parts
world,
India,
adopted
lockdown
to
curb
community
transmission
disease.
The
transportation,
access
health
facilities,
and
availability
medicines
consumables
as
well
outpatient
inpatient
services.
We
aimed
analyze
effect
imposed
due
COVID-19
on
kidney
diseases
in
India.MethodsWe
surveyed
19
major
hospitals
(8
public
11
private
sector)
determine
disease,
dialysis
after
first
3
weeks
lockdown.ResultsThe
total
number
these
centers
came
down
2517
2404.
Approximately
710
(28.2%)
missed
1
or
more
sessions,
69
(2.74%)
required
emergency
104
(4.13%)
stopped
reporting
for
dialysis,
9
(0.36%)
were
confirmed
have
died.
Outpatient
attendance
hospital
by
92.3%,
service
reduced
61%.
Tele-consultation
was
started
but
accessed
only
a
small
patients.ConclusionLack
preparedness
before
resulted
an
interruption
services
posed
immediate
adverse
outcome
India.
long-term
impact
less
severe
forms
remains
unknown.
Advances in Therapy,
Год журнала:
2021,
Номер
39(1), С. 33 - 43
Опубликована: Ноя. 5, 2021
Chronic
kidney
disease
(CKD)
is
a
complex
which
affects
approximately
13%
of
the
world's
population.
Over
time,
CKD
can
cause
renal
dysfunction
and
progression
to
end-stage
cardiovascular
disease.
Complications
associated
with
may
contribute
acceleration
risk
cardiovascular-related
morbidities.
Early
asymptomatic,
symptoms
only
present
at
later
stages
when
complications
arise,
such
as
decline
in
function
presence
other
comorbidities
In
advanced
disease,
significantly
impaired,
patients
be
treated
dialysis
or
transplant.
With
limited
treatment
options
available,
an
increasing
prevalence
both
elderly
population
set
rise.
This
review
discusses
current
challenges
unmet
patient
need
CKD.
Abstract
Organ‐on‐a‐chip
(OOC)
platforms
recapitulate
human
in
vivo‐like
conditions
more
realistically
compared
to
many
animal
models
and
conventional
two‐dimensional
cell
cultures.
OOC
setups
benefit
from
continuous
perfusion
of
cultures
through
microfluidic
channels,
which
promotes
viability
activities.
Moreover,
chips
allow
the
integration
biosensors
for
real‐time
monitoring
analysis
interactions
responses
administered
drugs.
Three‐dimensional
(3D)
bioprinting
enables
fabrication
multicell
with
sophisticated
3D
structures
that
closely
mimic
tissues.
3D‐bioprinted
are
promising
tools
understanding
functions
organs,
disruptive
influences
diseases
on
organ
functionality,
screening
efficacy
as
well
toxicity
drugs
organs.
Here,
common
techniques,
advantages,
limitations
each
method
reviewed.
Additionally,
recent
advances,
applications,
potentials
emulating
various
organs
presented.
Last,
current
challenges
future
perspectives
discussed.
